Physician profile
Michael Lawrence Will
NPI 1073876090
$7,634.79
in general payments reported to CMS, 2019-2025
44 companies · $1,101 in 2025
The $1,101 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $901 · 2020: $544 · 2021: $1,320 · 2022: $1,010 · 2023: $1,513 · 2024: $1,245 · 2025: $1,101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,860.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,859.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,393.83 | 2019-2025 | Xarelto, Spravato |
| Astrazeneca Pharmaceuticals LP | $1,238.13 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $602.15 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $481.77 | 2020-2025 | Mounjaro, Jardiance, Emgality |
| Pfizer INC. | $380.37 | 2019-2025 | |
| Glaxosmithkline, LLC. | $365.62 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $347.57 | 2019-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $286.51 | 2019-2025 | Jardiance, Spiriva Respimat, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $198.51 | 2021-2025 | |
| Abbott Laboratories | $184.13 | 2021-2025 | Proclaim, Freestyle Libre 3, Octrode |
| Novartis Pharmaceuticals Corporation | $181.30 | 2021-2022 | |
| Almatica Pharma LLC | $167.52 | 2022-2025 | Loreev Xr, Teriparatide |
| Abbvie INC. | $165.28 | 2021-2025 | Ubrelvy |
| Daiichi Sankyo INC. | $153.81 | 2019-2022 | |
| Antares Pharma, INC. | $133.50 | 2019-2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Will listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.